GlassScriptPhysician profile
Richard Banning
NPI 1346355278
$1,105.06
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $319 · 2021: $12.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $124.25 | 2019 | |
| Amgen INC. | $96.10 | 2019-2020 | |
| Amarin Pharma, INC. | $95.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $90.73 | 2019-2020 | |
| Glaxosmithkline, LLC. | $85.06 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.26 | 2019-2020 | |
| Sanofi Pasteur INC. | $65.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $60.82 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $59.02 | 2019-2020 | |
| Novo Nordisk INC | $54.26 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $52.76 | 2019-2021 | |
| Astellas Pharma US INC | $52.19 | 2019 | |
| Lilly USA, LLC | $51.47 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.64 | 2019 | |
| Allergan, INC. | $30.05 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $24.76 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.87 | 2019 | |
| Portola Pharmaceuticals, LLC | $11.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Banning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.